Please login to the form below

Not currently logged in
Email:
Password:

Chiesi

This page shows the latest Chiesi news and features for those working in and with pharma, biotech and healthcare.

Chiesi's ultra-rare genetic disorder therapy wins European backing

Chiesi's ultra-rare genetic disorder therapy wins European backing

Chiesi's ultra-rare genetic disorder therapy wins European backing. Lamzede is set to become the first approved therapy for Alpha-Mannosidosis. ... It’s the second most advanced product from Chiesi’s rare disease unit after its LSCD therapy Holoclar

Latest news

More from news
Approximately 12 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    GSK, AZ and Chiesi are each playing in this new market.

  • Deal Watch May 2016 Deal Watch May 2016

    911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.

  • Anticipating the future in healthcare Anticipating the future in healthcare

    The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy. ... Paolo Chiesi, chairman of the board of directors, and Andrea Chiesi, CEO of Chiesi Farmaceutici, are part of

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... 2. Global rights excluding India, Pakistan and China. 3. Acquisition of the shares not

  • Pharma deals during October 2012 Pharma deals during October 2012

    In keeping with Chiesi's marketing capabilities, the licence is for certain countries, including Europe, Turkey and CIS countries. ... 58. † Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence. LCP-Tacro (tacrolimus) immunosuppressant for kidney

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • CAN advertising

    AbbVie. ALK. Chiesi. Eisai. KIMS. LEO Pharma. Otsuka. Sanofi Pasteur MSD.

  • M&F Health

    Alere. British Association for Sexual Health and HIV (BASHH). Chiesi. Danone.

  • Random42 Scientific Communication

    Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics.

  • Swordfish Advertising

    Archimedes Pharma. Corporate. Chiesi. Fostair. Corporate. Clenil. Atimos. Danone. Infant feeding.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics